Drugs / TAEK-VAC-HerBy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04246671 | Aug 2020 → Feb 2024 | HER2 positive breast carcinoma, chordoma | Bavarian Nordic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAEK-VAC-HerBy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04246671 ↗ |
| Modality | Vaccine | “TAEK-VAC-HerBy vaccine” NCT04246671 ↗ |
| Route | Intravenous | “administered intravenously” NCT04246671 ↗ |